Why the study?
Does nesiritide improve hemodynamics and clinical status in patients hospitalized with decompensated congestive heart failure?
Does nesiritide improve hemodynamics and clinical status in patients hospitalized with decompensated congestive heart failure?
Nesiritide is an effective parenteral agent for rapidly improving hemodynamics and clinical status in decompensated heart failure.
May support nesiritide for acute hemodynamic relief in decompensated HF; leaves open long-term outcomes versus contemporary therapies.
Nesiritide (Natrecor), a synthetic formulation of B-type natriuretic peptide (BNP), is the first new parenteral agent to be approved for treating heart failure in more than a decade. In patients hospitalized with decompensated congestive heart failure, nesiritide promptly reduces pulmonary capillary wedge pressure, pulmonary arterial pressure, right atrial pressure, and systemic vascular resistance, resulting in clinical improvement.
No takes yet. Share an insight, caveat, or question.
Mills et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: